A. sativum was chosen as the target drug in the study to inhibit myointimal hyperplasia because, according to Efendy et al., Campbell et al. and Yamaji et al., it has an anti-atherosclerotic effect. Moreover, according to Lau, A. sativum has a hypocholesterolemic effect; furthermore, Borek reported that it has antitumor, anti-inflammatory, and antioxidant effects. Hence, there was a great possibility that A. sativum would act favorably in the inhibition of myointimal hyperplasia. The dose of 800 µg.kg-1.day-1 was chosen as the test dose in the present study, as Efendy et al. reported that 800 µg.kg-1.day-1 of crude extract of garlic can inhibit the development of fat layers and the accumulation of cholesterol in the vessel walls, thus protecting them against the development of atherosclerosis. The use of A. sativum in its original form as based on the study by Borek, who found that allicin—a component of A. sativum — is unstable in solution, as it is a lipid-soluble, volatile organosulfur compound. Thus, it is essential that the maximum possible amount of the active substances of A. sativum is retained.